The Prostate · 2008 · 14 citations · 14 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyTumor MicroenvironmentAndrogen Deprivation TherapyBone MetastasisBone TumorsProstate CancerTumor ImagingTumor PromotionBone Metastatic ColonizationBone MorphometryBone Tumor MetastasisIn Vivo ImagingMicroscopic Bone LossProstate Cancer HistopathologyTumor Growth MonitoringTumor Volume Measurement
INTRODUCTION: Tumor populations may selectively colonize bone that is being actively remodeled. In prostate cancer patients, androgen deprivation directly inhibits tumor growth initially, whilst induced bone loss may facilitate tumor colonization of bone by androgen-insensitive cells. We have tested this hypothesis using a xenograft model of early growth of prostate cancer in bone. METHODS: PC3 cells transfected with Green fluorescent protein (GFP) were injected into castrated and non-castrated athymic mice via intrabial and intracardiac routes. In vivo tumor growth was monitored daily and animals sacrificed 6-9 days following initial GFP-based detection of tumors. Tumor bearing and contra-lateral non-tumor bearing tibias were analyzed extensively by micro-CT and histology/immunohistochemistry for the presence of tumor cells and the effects of tumor and/or castration on bone cells and bone structure evaluated. RESULTS: GFP-positive tumors in bone were visible from 12 days post-injection following intratibial injection, allowing tumors <1 mm diameter to be monitored in live animals. Castration did not affect tumor frequency, tumor volume, or time to initial appearance of tumors injected via intratibial or intracardiac routes. Castration decreased trabecular bone volume in all mice. Significant tumor-induced suppression of numbers of osteoblasts, coupled with increased numbers of activated osteoclasts, was evident in both intact animals and castrated animals. CONCLUSIONS: In vivo GFP imaging allows the detection of early tumor growth at intra-osseous sites. Castration induces bone loss, but PC3-GFP cells are also capable of inducing bone remodeling in intact animals at early time points, independently of pre-existing castration-induced alterations to bone.
14
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
John G. Emery, Peter McDonnell, Michael Brigham Burke et al. · Journal of Biological Chemistry · 1998 · 1.2K citations · Full text
Detection of hematogenous micrometastasis in patients with prostate cancer.
José Moreno, C M Croce, R. Fischer et al. · PubMed · 1992 · 364 citations
Prostate Cancer Cells Promote Osteoblastic Bone Metastases through Wnts
Christopher L. Hall, Anna Bafico, Jinlu Dai et al. · Cancer Research · 2005 · 305 citations · Full text
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Ingunn Holen, Peter I. Croucher, Freddie C. Hamdy et al. · PubMed · 2002 · 271 citations
Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved
Hiroshi Saitoh, Miho Hida, Takao Shimbo et al. · Cancer · 1984 · 251 citations